← Leaderboards
Jianhua Yu
Beckman Research Institute/City Of Hope
$11,234,533
Attributed
$15,546,464
Total exposure
13
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,240,036 · 14
By mechanism
R01$13,419,722 · 8
P01$1,693,572 · 1
U01$1,114,409 · 1
U19$487,902 · 2
R21$413,903 · 1
R41$110,528 · 1
Top collaborators
- Michael A Caligiuri13 shared
- Miguel Angel Villalona4 shared
- Lihua Elizabeth Budde3 shared
- William E. Carson2 shared
- Peixuan Guo2 shared
- Henry Marsh2 shared
- Daniel W Pack2 shared
- E. Antonio Chiocca1 shared
Most similar at Beckman Research Institute/City Of Hope
Same institution · by research overlap
- Lihua Elizabeth Budde$959,566
- Behnam Badie$11,237,051
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsIn VivoCellsNatural Killer CellsTumorImmuneSignal TransductionBaseNeoplastic CellChimeric Antigen ReceptorIn VitroCytotoxicityCell PhysiologyCancer TherapyMediatingMouse ModelGlioblastomaReceptorReportingCytokineBloodEngineeringImmune ResponseImmunotherapy
Grant awards (46)
Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors$562,792
R01 · FY2025 · CA
Characterizing and Targeting the Novel IL-15- AKT-XBP1s Pathway in NK Cells$423,402
R01 · FY2024 · CA · contact PI
Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia$479,375
R01 · FY2023 · CA
Characterizing and Targeting the Novel IL-15- AKT-XBP1s Pathway in NK Cells$436,772
R01 · FY2023 · CA · contact PI
Overcoming Barriers of Virotherapy by Next-Generation oHSV Expressing E-Cadherin$374,912
R01 · FY2023 · NS · contact PI
Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors$358,924
R01 · FY2023 · CA
Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors$253,630
R01 · FY2023 · CA
An engineered oncolytic herpes virus expressing a full-length α-CD47 mAb for the treatment of GBM$155,233
U19 · FY2023 · CA · contact PI
Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors$620,673
R01 · FY2022 · CA
Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia$479,375
R01 · FY2022 · CA
Characterizing and Targeting the Novel IL-15- AKT-XBP1s Pathway in NK Cells$436,772
R01 · FY2022 · CA · contact PI
Overcoming Barriers of Virotherapy by Next-Generation oHSV Expressing E-Cadherin$374,912
R01 · FY2022 · NS · contact PI
An engineered oncolytic herpes virus expressing a full-length α-CD47 mAb for the treatment of GBM$158,755
U19 · FY2022 · CA · contact PI
Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia$489,159
R01 · FY2021 · CA
Characterizing and Targeting the Novel IL-15- AKT-XBP1s Pathway in NK Cells$445,687
R01 · FY2021 · CA · contact PI
Elucidate and Modulate Cell Signaling in NK Cells for Glioma Treatment$420,175
R01 · FY2021 · AI · contact PI
An engineered oncolytic herpes virus expressing a full-length α-CD47 mAb for the treatment of GBM$173,914
U19 · FY2021 · CA · contact PI
Characterizing and Targeting the Novel IL-15- AKT-XBP1s Pathway in NK Cells$445,687
R01 · FY2020 · CA · contact PI
Elucidate and Modulate Cell Signaling in NK Cells for Glioma Treatment$420,323
R01 · FY2020 · AI · contact PI
Overcoming Barriers of Virotherapy by Next-Generation oHSV Expressing E-Cadherin$380,692
R01 · FY2020 · NS · contact PI
scFvPD1-FLT3 CAR T Cells for the Treatment of Relapsed Acute Myeloid Leukemia$188,138
R21 · FY2020 · CA · contact PI
Elucidate and Modulate Cell Signaling in NK Cells for Glioma Treatment$428,701
R01 · FY2019 · AI · contact PI
Overcoming Barriers of Virotherapy by Next-Generation oHSV Expressing E-Cadherin$387,382
R01 · FY2019 · NS · contact PI
Enhancing NK Cell Activity by Dietary Diphyllin Lignans for Cancer Prevention$383,865
R01 · FY2019 · CA · contact PI
IL-15 Characterization Through Experimental Immunology$334,667
R01 · FY2019 · CA · contact PI
scFvPD1-FLT3 CAR T Cells for the Treatment of Relapsed Acute Myeloid Leukemia$225,765
R21 · FY2019 · CA · contact PI
Elucidate and Modulate Cell Signaling in NK Cells for Glioma Treatment$386,136
R01 · FY2018 · AI · contact PI
Enhancing NK Cell Activity by Dietary Diphyllin Lignans for Cancer Prevention$352,275
R01 · FY2018 · CA · contact PI
Overcoming Barriers of Virotherapy by Next-Generation oHSV Expressing E-Cadherin$348,382
R01 · FY2018 · NS · contact PI
IL-15 Characterization Through Experimental Immunology$175,175
R01 · FY2018 · CA · contact PI
IL-15 Characterization Through Experimental Immunology$154,000
R01 · FY2018 · CA · contact PI
Elucidate and Modulate Cell Signaling in NK Cells for Glioma Treatment$42,370
R01 · FY2018 · AI · contact PI
Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas$1,693,572
P01 · FY2017 · CA · contact PI
Optimizing RNA nanoparticles size and shape for enhancing cancer targeting and treatment$561,330
U01 · FY2017 · CA
Elucidate and Modulate Cell Signaling in NK Cells for Glioma Treatment$387,500
R01 · FY2017 · AI · contact PI
Enhancing NK Cell Activity by Dietary Diphyllin Lignans for Cancer Prevention$352,275
R01 · FY2017 · CA
IL-15 Characterization Through Experimental Immunology$329,175
R01 · FY2017 · CA · contact PI
Optimizing RNA nanoparticles size and shape for enhancing cancer targeting and treatment$553,079
U01 · FY2016 · CA
Enhancing NK Cell Activity by Dietary Diphyllin Lignans for Cancer Prevention$352,275
R01 · FY2016 · CA
IL-15 Characterization Through Experimental Immunology$329,175
R01 · FY2016 · CA
Enhancing NK Cell Activity by Dietary Diphyllin Lignans for Cancer Prevention$352,275
R01 · FY2015 · CA
Elucidate and Modulate TGF-b Signaling in NK Cells for Glioma Treatment$306,944
R01 · FY2014 · CA · contact PI
Elucidate and Modulate TGF-b Signaling in NK Cells for Glioma Treatment$297,451
R01 · FY2013 · CA · contact PI
CDX-301 and Plerixafor Combination in Stem Cell Mobilization for Transplantation$100,000
R41 · FY2013 · OD
CDX-301 and Plerixafor Combination in Stem Cell Mobilization for Transplantation$10,528
R41 · FY2013 · OD
Elucidate and Modulate TGF-b Signaling in NK Cells for Glioma Treatment$316,437
R01 · FY2012 · CA · contact PI